Article info
Extended report
Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?
- Prof. Christopher P Denton, Centre for Rheumatology, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London, NW3 2PF, UK; c.denton{at}rfc.ucl.ac.uk
Citation
Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?
Publication history
- Accepted June 3, 2007
- First published June 29, 2007.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2008 BMJ Publishing Group and European League Against Rheumatism